You are viewing an incomplete version of our website. Please click to reload the website as full version.

anti-Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antibodies

CDKN2A generates several transcript variants which differ in their first exons.

list all antibodies Gene Name GeneID UniProt
Anti-Rat CDKN2A CDKN2A 25163 Q9R0Z3
Anti-Human CDKN2A CDKN2A 1029 P42771,Q8N726
Anti-Mouse CDKN2A CDKN2A 12578 P51480,Q64364
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online

More Antibodies against Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Interaction Partners

Human Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) interaction partners

  1. These results indicate that the loss of RB1 (show RB1 Antibodies) and CDKN2A function induces distinctively different signaling cascades in non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma

  2. Data show that Y box binding protein 1 (YBX1 (show YBX1 Antibodies)) positively controls the Internal Ribosome Entry Site (IRES) activity of the wild type, full-length CDKN2A/p16INK4a 5'-untranslated region (5'UTR (show UTS2R Antibodies)).

  3. Point mutations in TP53 (show TP53 Antibodies) but not in p15(Ink4b (show CDKN2B Antibodies)) and p16(Ink4a) genes represent poor prognosis factors in acute adult T cell leukemia/lymphoma

  4. p16 expression is associated with better response to definitive combined treatment (RCT (show FOXE3 Antibodies), RT + cetuximab), but also significantly related to acute high-grade toxicity.

  5. p16 status was strongly prognostic for patients with oropharyngeal squamous cell carcinoma. The data suggest that the addition of cetuximab to radiotherapy improved clinical outcomes regardless of p16 or HPV status versus RT alone.

  6. Study provides clear evidence that p16 is a suppressor of the oncogenic ERK (show EPHB2 Antibodies) pathway and its effect is mediated via miR (show MLXIP Antibodies)-21-5p inhibition in osteosarcoma cells.

  7. The circulating auto-antibody to P16 may be one of a series of potential biomarkers with early prognostic values for cervical cancer.

  8. These findings point to (i) the relevance of CS-related mechanisms in Hodgkin lymphoma , and to (ii) the prognostic value of a simple, reproducible, and low-cost immunohistochemical evaluation of p16(INK4a) and p21(CIP1/WAF1 (show CDKN1A Antibodies)) expression.

  9. p16(INK4a) expression is reduced with advancing tumor stage and its gene silencing is associated with an increased risk of death.

  10. In 22 lung cancer patients with negative histology and cytology at initial bronchoscopy, FHIT and p16 mRNA loss was detected in 40.9% (9/22) and 36.4% (8/22) cases, respectively.

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) interaction partners

  1. that MEK (show MDK Antibodies) activity induced cell cycle arrest through accumulation of p16/19(cdkn2a)

  2. Data indicate the cyclin-dependent kinase inhibitor 2A (p19Arf) and interferon beta (IFN-beta (show IFNB1 Antibodies)) combination as a cancer immunotherapy strategy.

  3. Our findings reveal a novel role for p16(Ink4a) and cellular senescence in promoting insulin (show INS Antibodies) secretion by beta cells and in regulating normal functional tissue maturation with age.

  4. Loss of Nf2 (show NF2 Antibodies) and Cdkn2a/b have synergistic effects with PDGF-B (show PDGFB Antibodies) overexpression promoting meningioma malignant transformation.

  5. Inactivation of INK4a and ARF induces myocardial proliferation and improves cardiac repair following ischemiareperfusion

  6. loss of p19ARF overcomes senescence of LSECs, allowing immortalization of cells without losing endothelial characteristics.

  7. Increased gene dosage of Ink4a, Arf1 (show ARF1 Antibodies) and p53 (show TP53 Antibodies) delays age-associated central nervous system functional decline.

  8. Dysregulation of the Bmi-1 (show BMI1 Antibodies)/p16Ink4a pathway provokes an aging-associated decline of submandibular gland function.

  9. Results show that epigenetic silencing of p16(Ink4a) in selected liver cells bypassing senescence is a general principle for development of liver tumors with beta-catenin (show CTNNB1 Antibodies) involvement in mice independent of the initial stimulus.

  10. Results show that p53 (show TP53 Antibodies) and ARF are required for a senescence response in breast cells following oncogenic mutation while they are dispensable to an apoptosis response and that ARF gene function provides a critical barrier to mammary tumorigenesis.

Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antigen Profile

Protein Summary

This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene\; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.

Gene names and symbols associated with CDKN2A

  • cyclin-dependent kinase inhibitor 2A (Cdkn2a) antibody
  • cyclin-dependent kinase inhibitor 2A (LOC100340625) antibody
  • cyclin-dependent kinase inhibitor 2A (CDKN2A) antibody
  • ARF antibody
  • ARF-INK4a antibody
  • CDK4I antibody
  • CDKN2 antibody
  • CMM2 antibody
  • INK4 antibody
  • INK4A antibody
  • INK4a-ARF antibody
  • Ink4a/Arf antibody
  • MLM antibody
  • MTS-1 antibody
  • MTS1 antibody
  • P14 antibody
  • P14ARF antibody
  • P16 antibody
  • p16(INK4a) antibody
  • P16-INK4A antibody
  • p16Cdkn2a antibody
  • P16INK4 antibody
  • p16INK4a antibody
  • P19 antibody
  • p19 antibody
  • P19ARF antibody
  • Pctr1 antibody
  • TP16 antibody

Protein level used designations for CDKN2A

CDK4I , Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4) , cell cycle inhibitor , cell cycle regulator , cyclin-dependent kinase 4 inhibitor A , cyclin-dependent kinase inhibitor 2a p16Ink4a , cyclin-dependent kinase inhibitor 2a p19Arf , p16-INK4 , p16-INK4a , CDK4 inhibitor p16-INK4 , cell cycle negative regulator beta , cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) , multiple tumor suppressor 1 , cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4) , cyclin-dependent kinase inhibitor 2A, isoforms 1/2 , cyclin-dependent kinase inhibitor protein , mitochondrial smARF

25163 Rattus norvegicus
100731972 Cavia porcellus
100340625 Oryctolagus cuniculus
1029 Homo sapiens
12578 Mus musculus
Did you look for something else?